Stock FENNEC PHARMACEUTICALS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Fennec Pharmaceuticals Inc Other OTC

Equities

CA31447P1009

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating
MT
Fennec Pharmaceuticals : Corporate Presentation May 2024
PU
Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024
Fennec Pharmaceuticals Swings to Q1 Profit on Higher Sales, Licensing Revenue
MT
Fennec Pharmaceuticals Brief: Company Says Has Approximately US$51 Million in Cash, Cash Equivalents, and Investment Securities
MT
Fennec Pharmaceuticals Brief: Achieved Q1 2024 Total Net Revenues of US$25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction
MT
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Fennec Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
GL
Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing
MT
Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing
MT
Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing
MT
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing
MT
HC Wainwright Raises Fennec Pharmaceuticals Price Target to $18 From $17, Maintains Buy Rating
MT
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing
MT
Fennec Pharmaceuticals : Corporate Presentation March 2024
PU
Wedbush on Fennec's Q4
MT
Transcript : Fennec Pharmaceuticals Inc., 2023 Earnings Call, Mar 21, 2024
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share
MT
Fennec Pharmaceuticals Brief: Cited Pro forma fourth quarter cash in excess of US$55 million
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FENC Stock
  4. Stock
  5. News Fennec Pharmaceuticals Inc